Literature DB >> 15481267

Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer.

C Vogelberg1, H J Kremer, B Ellers-Lenz, M Engel, J Maus, F Conrad, R Hermann.   

Abstract

STUDY
OBJECTIVE: To assess whether asthmatic children may generate sufficient peak inspiratory flow through the Novolizer, a novel multiple dose dry powder inhaler with acoustic and optical feedback mechanisms for correct inhalation. PATIENTS AND METHODS: 137 children (median age 7 years, range 4-2) with mild to moderate persistent asthma (FEV1 < 90% predicted or pre-treated with low-dose steroids) participated in this open, multi-centre study. After assessment of FEV1 and peak inspiratory flow (without inhalator device, PIF), the children were instructed to inhale with the Novolizer (PIF through inhaler, PIF-N). All assessments were done in triplicate and the mean out of three attempts analysed.
RESULTS: Mean PIF was 128 +/- 61 l/min and mean PIF-N was 69 +/- 18 l/min. This is distinctly above the rate necessary to overcome the Novolizer's trigger threshold. PIF performance through the Novolizer was linear in the age interval of 4-8 years, no further increase was observed beyond 8 years.
CONCLUSIONS: The medium to low intrinsic resistance of the Novolizer permits a relatively high PIF through this device. Together with the feedback mechanisms, this makes the Novolizer particularly valuable for inhalation therapy in asthmatic children with drugs such as salbutamol, formoterol, or budesonide.

Entities:  

Mesh:

Year:  2004        PMID: 15481267     DOI: 10.1016/j.rmed.2004.03.024

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

Review 1.  Novolizer: a multidose dry powder inhaler.

Authors:  Caroline Fenton; Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze.

Authors:  Wim M van Aalderen; Luis Garcia-Marcos; Monika Gappa; Warren Lenney; Søren Pedersen; Richard Dekhuijzen; David Price
Journal:  NPJ Prim Care Respir Med       Date:  2015-01-08       Impact factor: 2.871

Review 3.  The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.

Authors:  Andrew R Clark; Jeffry G Weers; Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-10-31       Impact factor: 2.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.